Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIER trial in relapsed or refractory primary central nervous system lymphoma
ISRCTN12857473Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, ifosfamide, etoposide and rituximab in primary central nervous system lymphoma (PCNSL), sponsored by University of Birmingham. Primary endpoint: Maximum tolerated dose of thiotepa in combination with ifosfamide, etoposide and rituximab. Started Dec 2014; status: completed.
02
Drugs
thiotepaifosfamideetoposiderituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ISRCTN12857473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12857473.